RxDoctor Payments Data

Sarah Larocco

Nurse Practitioner · Reidsville, NCNPI 1285182295

Payments from drug & device makers

$4,338in general payments, 2019–2025

Across 66 payments — averaging $65.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Medtronic$1K
  • Sumitomo Pharma America, Inc.$262
  • Otsuka America Pharmaceutical, Inc.$245
  • Novo Nordisk$181
  • Merck$176
  • plus $1K from 17 others
$280in research payments, 2019–2025

Across 1 payment — averaging $280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$280

What the payments were for

  • Travel & lodging$1,54936%
  • Food & beverage$2,77064%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,338 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,058
Medicare patients
214
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron253$153,994
ElmironPentosan Polysulfate Sodium100$118,117
GemtesaVibegron73$38,383
Estradiol149$13,367
PremarinEstrogens, Conjugated12$5,291
Methenamine Hippurate51$4,137
Hydroxyzine Hcl137$2,719
Trimethoprim69$2,583
Tamsulosin Hcl198$2,238
Desmopressin Acetate18$1,417
Solifenacin Succinate51$1,231
Amitriptyline Hcl115$1,146
Tolterodine Tartrate14$1,142
Silodosin13$979
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$262$38,38373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Reidsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →